2254931 is referenced by 4 patents.

Disclosed is a process for obtaining hybridoma cell lines which produce human antibodies capable of binding to the hepatitis B virus surface antigen (HBVsAg), as well as the hybridoma cell lines, and antibodies produced by the cell lines. Also disclosed are various uses of said antibodies in the prevention and treatment of HBV infection. Peripheral blood lymphocytes obtained from human donors having a high titer of anti HBVsAg antibodies are engrafted into normal strains of mice which were lethally irradiated and radioprotected with SCID bone marrow. After immunization of such chimeric mice with HBVsAg, human cells are obtained from the mice spleens and fused in vitro with heteromyeloma cells to generate hybridomas secreting human antibodies having a high affinity and specificity to HBVsAg.

Title
Anticorps monoclonaux humains se fixant sur lantigene de surface de lhepatite b
Human monoclonal antibodies to the hepatitis b surface antigen
Publication Number
2254931
Application Date
June 10, 1997
Publication Date
December 18, 1997
Inventor
Dagan Shlomo
Reisner Yair
Agent
SMART & BIGGAR
Assignee
Xtl Biopharmaceuticals
Yeda Research And Development
Assignee
Xtl Biopharmaceuticals
Yeda Research And Development
IPC
G01N 33/577
G01N 33/576
C07K 16/08
A61K 39/42
A61K 39/00
A61K 38/00
A01K 67/027
C12N 05/28
View Original Source